Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Millan

Showing results (211-220 of 224) with videos related to

Pageof 23
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|September 11, 1998
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidolM J Millan, A Gobert, A Newman-Tancredi, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1995
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsyM J Millan, J L Peglion, J Vian, et al.
Molecular Psychiatry|August 27, 2014
Local inactivation of Gpr88 in the nucleus accumbens attenuates behavioral deficits elicited by the neonatal administration of phencyclidine in ratsM Ingallinesi, L Le Bouil, N Faucon Biguet, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 9, 1998
A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194V Audinot, A Newman-Tancredi, A Gobert, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1997
S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic propertiesM J Millan, S Hjorth, R Samanin, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1992
S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptorsM J Millan, J M Rivet, H Canton, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 9, 1998
S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and racloprideM J Millan, A Newman-Tancredi, M Brocco, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 1998
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidolM J Millan, R Schreiber, A Dekeyne, et al.
Synapse (New York, N.Y.)|December 28, 1999
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive statesM J Millan, A Newman-Tancredi, V Audinot, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 18, 2001
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterizationM J Millan, D Cussac, G Milligan, et al.
Pageof 23

Showing results (211-220 of 224) with videos related to

Sort By:
Pageof 23
The Journal of Pharmacology and Experimental Therapeutics|September 11, 1998
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidolM J Millan, A Gobert, A Newman-Tancredi, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1995
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsyM J Millan, J L Peglion, J Vian, et al.
Molecular Psychiatry|August 27, 2014
Local inactivation of Gpr88 in the nucleus accumbens attenuates behavioral deficits elicited by the neonatal administration of phencyclidine in ratsM Ingallinesi, L Le Bouil, N Faucon Biguet, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 9, 1998
A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194V Audinot, A Newman-Tancredi, A Gobert, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1997
S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic propertiesM J Millan, S Hjorth, R Samanin, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1992
S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptorsM J Millan, J M Rivet, H Canton, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 9, 1998
S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and racloprideM J Millan, A Newman-Tancredi, M Brocco, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 1998
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidolM J Millan, R Schreiber, A Dekeyne, et al.
Synapse (New York, N.Y.)|December 28, 1999
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive statesM J Millan, A Newman-Tancredi, V Audinot, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 18, 2001
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterizationM J Millan, D Cussac, G Milligan, et al.
Pageof 23